Table 2.
Target | Inhibitor | Action | Result | Model | Reference |
---|---|---|---|---|---|
PRX1 | Pentagamavunon-1 (PGV-1), a curcumin analog | Bound to several ROS-metabolizing enzymes, including PRX1 | Induced G2/M cell cycle arrest and cell senescence | Highly metastatic breast cancer cell line, the 4T1 cells | [109] |
PRX1 | Epo-C12, a synthetic derivative of epolactaene | Inhibit PRX1 peroxidase but not its chaperone activity. | Exerted an apoptotic effect | BALL-1 cells | [110] |
PRX1 | Ferulic Acid Amides | Inhibit peroxidase activity | Improved hyperglycemia and hyperlipidemia | Streptozotocin-nicotinamide-induced diabetic rats | [111] |
PRX1 | Frenolicin B | Target the active cysteine residues | Increased levels of intracellular ROS to induce apoptosis and suppress tumor growth | Nude mice bearing established HCT116 or DLD-1 colorectal cancer xenografts | [108] |
PRX2 | Conoidin A | Inhibit peroxidase activity | Inhibited the growth of the 5-FU-resistant gastric cancer SNU620 cells | 5-FU-resistant SNU620 cells | [112,113] |
PRX1 /PRX2 |
Adenanthin, a diterpenoid isolated from the leaves of Rabdosia adenantha | Inhibit enzymes of the PRX-related chain including thioredoxin and thioredoxin reductase | Induced differentiation of acute promyelocytic leukemia (APL) expresses tumor growth in vivo and prolongs survival | Mouse APL models | [114] |
Killed these malignant liver cells in vitro and xenografts | SMMC-7721 cells were transplanted into BALB/c nude mice | [115] | |||
Impaired the spontaneous and antibody-dependent NK cell cytotoxicity against cancer cells | K562 and Raji cell lines, primary human NK cells | [53] | |||
PRX1 /PRX2 |
Parvifoline AA | Inhibit peroxidase activity | Activated the ROS/ERK axis and the immunogenicity of hepatocellular carcinoma toward natural killer cells. | Hepa1-6 mouse allograft model | [116] |
PRX6 | 9 amino acid peptide named as PIP-2 | Inhibit of PRX6 Phospholipase A 2 Activity | Protected against Lung Injury | Mouse Model of Ventilator-Induced Lung Injury | [117] |